What question did this study set out to answer?

July 1, 2005Diabetes CareOpen Access

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

View Full Paper

Ask AI

Bookmark

Authors

RGRonald GoldbergNOAA National Marine Fisheries Service DKDavid M. KendallZealand Pharma (Denmark)MDMark A. DeegCompugen (Israel)

Discussion

Member takes

Implication

Randomized trial demonstrates superior lipid improvements with pioglitazone over rosiglitazone in type 2 diabetes with dyslipidemia, suggesting distinct cardiovascular risk profiles.

Key Points

To directly compare the lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and untreated dyslipidemia.
Randomized trial of patients with type 2 diabetes and dyslipidemia not taking lipid-lowering therapies, following a 4-week placebo washout period.
Participants were randomly assigned to pioglitazone (n = 400; 30 mg daily for 12 weeks, then 45 mg daily for 12 weeks) or rosiglitazone (n = 402; 4 mg daily for 12 weeks, then 4 mg twice daily for 12 weeks).
Triglyceride levels decreased by 51.9 ± 7.8 mg/dl with pioglitazone versus an increase of 13.1 ± 7.8 mg/dl with rosiglitazone (P < 0.001).
Pioglitazone produced a greater increase in HDL cholesterol (5.2 ± 0.5 vs. 2.4 ± 0.5 mg/dl; P < 0.001) and a smaller increase in LDL cholesterol (12.3 ± 1.6 vs. 21.3 ± 1.6 mg/dl; P < 0.001) than rosiglitazone.
LDL particle concentration decreased with pioglitazone but increased with rosiglitazone (P < 0.001), while LDL particle size increased more with pioglitazone (P = 0.005).

Cite This Study

Goldberg et al. (2005) studied this question.

synapsesocial.com/papers/6a7f25b96cdc9ba79316c07f https://doi.org/10.2337/diacare.28.7.1547

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates superior lipid improvements with pioglitazone over rosiglitazone in type 2 diabetes with dyslipidemia, suggesting distinct cardiovascular risk profiles.

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Discussion

Member takes

Implication

Key Points

Cite This Study

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider